1-9 of 9
Sue E. Bell
Close
Sort by
Journal Articles

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Clinical Trials & Observations Brief Report
Andy C. Rawstron, Walter M. Gregory, Ruth M. de Tute, Faith E. Davies, Sue E. Bell, Mark T. Drayson, Gordon Cook, Graham H. Jackson, Gareth J. Morgan, J. Anthony Child, Roger G. Owen
Journal: Blood
Blood (2015) 125 (12): 1932–1935.
https://doi.org/10.1182/blood-2014-07-590166
Published: 2015
Includes: Supplemental data
Journal Articles

Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial

Charlotte Pawlyn, MD, Faith E. Davies, MD, Walter M Gregory, PhD, Alex J Szubert, MSc, Sue E Bell, DPhil, Jacqueline Ouzman, PhD, Mark T Drayson, MD, Roger G Owen, MD, Graham H Jackson, MD, Nigel H Russell, MD, Gareth J. Morgan, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 335.
https://doi.org/10.1182/blood.V120.21.335.335
Published: 2012
Journal Articles

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

Clinical Trials & Observations
Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Alex J. Szubert, Sue E. Bell, Mark T. Drayson, Roger G. Owen, A. John Ashcroft, Graham H. Jackson, J. Anthony Child
Journal: Blood
Blood (2012) 119 (23): 5374–5383.
https://doi.org/10.1182/blood-2011-11-392522
Published: 2012
Includes: Supplemental data
Journal Articles

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Clinical Trials & Observations
Gareth J. Morgan, Walter M. Gregory, Faith E. Davies, Sue E. Bell, Alexander J. Szubert, Julia M. Brown, Nuria N. Coy, Gordon Cook, Nigel H. Russell, Claudius Rudin, Huw Roddie, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group
Journal: Blood
Blood (2012) 119 (1): 7–15.
https://doi.org/10.1182/blood-2011-06-357038
Published: 2012
Includes: Supplemental data
Journal Articles

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

Gareth J Morgan, MD PhD, Faith E Davies, MD, Walter M Gregory, PhD, Sue E Bell, DPhil, Alex J Szubert, MSc, Gordon Cook, Mark T Drayson, MD, Roger G Owen, MD, Fiona M Ross, DPhil, Graham H Jackson, MD, J. Anthony Child, MD
Journal: Blood
Blood (2011) 118 (21): 993.
https://doi.org/10.1182/blood.V118.21.993.993
Published: 2011
Journal Articles

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Clinical Trials & Observations
Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Nigel H. Russell, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Jenny L. Byrne, Huw Roddie, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, for the NCRI Haematological Oncology Study Group
Journal: Blood
Blood (2011) 118 (5): 1231–1238.
https://doi.org/10.1182/blood-2011-02-338665
Published: 2011
Includes: Supplemental data
Journal Articles

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M. Gregory, PhD, Sue E. Bell, PhD, Alex J. Szubert, MSc, Nuria Navarro-Coy, MPhil, Mark T. Drayson, MD, PhD, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, PhD, Graham H. Jackson, MD, J. Anthony Child, MD
Journal: Blood
Blood (2010) 116 (21): 623.
https://doi.org/10.1182/blood.V116.21.623.623
Published: 2010
Journal Articles

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M Gregory, Sue E. Bell, DPhil, Alexander J Szubert, MSc, Mark T. Drayson, MD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, Dr, Graham H. Jackson, MD, Nigel H. Russell, MD, J. Anthony Child, MD
Journal: Blood
Blood (2010) 116 (21): 311.
https://doi.org/10.1182/blood.V116.21.311.311
Published: 2010
Journal Articles

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

David C. Johnson, Sophie Corthals, Christine Ramos, Antje Hoering, Kim Cocks, Nicholas J. Dickens, Jeff Haessler, Harmut Goldschmidt, J. Anthony Child, Sue E. Bell, Graham Jackson, Dalsu Baris, S. Vincent Rajkumar, Faith E. Davies, Brian G. M. Durie, John Crowley, Pieter Sonneveld, Brian Van Ness, Gareth J. Morgan
Journal: Blood
Blood (2008) 112 (13): 4924–4934.
https://doi.org/10.1182/blood-2008-02-140434
Published: 2008
Includes: Supplemental data